New hope for Hard-to-Treat cancers: experimental drug PRTH-101 enters human testing
Disease control
Recruiting now
This early-phase study tests a new drug called PRTH-101, alone or with an approved immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if …
Phase: PHASE1 • Sponsor: Incendia Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:43 UTC